• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·CYDX
Share

CYduct Diagnostics, Inc. Stocks

$ 2.7Last Updated 24.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 14.15M

$ 2.7
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

CYduct Diagnostics, Inc. operates as a medical instrument enterprise that engineers and commercializes a diverse range of technologies, equipment, and methodologies. These innovations are purposed for the detection, diagnosis, therapeutic intervention, and general management of various health conditions and illnesses. The company's extensive product offerings include specialized breast endoscopy systems, an assortment of camera solutions (such as 3-chip and 1-chip models), and all necessary accessories. They also provide a broad selection of endoscopic instruments, encompassing surgical tools like dissectors, graspers, scissors, needle holders, fan retractors, cautery devices, and insufflation needles. Furthermore, CYduct supplies illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps, alongside insufflators. For surgical specialties, their portfolio features laparoscopic instruments designed for general surgery, lymphadenectomy, gynecology, and thorascopy. Complementing these are rigid scopes (like laparoscopes, operative scopes, and cystoscopes) with their corresponding accessories, as well as trocar and cannula sets, video carts, and both insulated and non-insulated instrument handles. Uniquely, the company also provides instrumentation tailored for veterinary applications. Established in 1986, CYduct Diagnostics, Inc. is headquartered in Westport, Connecticut. The firm was formerly known as Solos Endoscopy, Inc., before adopting its current name in December 2020.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 15:50

July Could Be the Worst Month for Chinese Stocks in 10 Years

30.07.2026 15:40

Morning in New York: Focus on Inflation Data, New Reports from Big Tech, and Geopolitics

30.07.2026 15:00

IPO Reformation: The Brand That Dressed Taylor Swift and Jennifer Aniston Goes Public

30.07.2026 14:59

Jersey Mike’s IPO: Shares of the sandwich bar chain challenging Subway are now available

30.07.2026 14:34

Central banks sharply reduced their gold purchases in early 2026—to a 15-year low

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026